|100.04|| +0.61 / +0.61%|
Edwards Lifesciences Corp. is focused on technologies that treat structural heart disease and critically ill patients. It designs, develops, manufactures and markets products to treat stage cardiovascular disease. Its products and technologies are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves and Critical Care. The Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Critical Care portfolio products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. Edwards Lifesciences was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
|Michael A. Mussallem||Chairman & Chief Executive Officer|
|Scott B. Ullem||Chief Financial Officer & Vice President|
|Stanton J. Rowe||Chief Scientific Officer & VP-Advanced Technology|
|John P. McGrath||Vice President-Quality, Regulatory & Clinical|
|Aimee S. Weisner||Vice President & General Counsel|